wire - news in brief


Category


Years
2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008

Last News


Results 301 - 321 of 321.

Life Sciences - Psychology
04.10.2016
Do Older People Take Fewer Risks?
Studies by the University of Basel have shown that whether and how risk-taking propensity varies over a person's life span depends in part on how risk taking is measured. When subjects are asked how they assess their risk propensity, a clear reduction with age is the result. However, this reduction is not necessarily observed for specific risk-taking tasks.
Medicine/Pharmacology - Life Sciences
04.10.2016
US FDA grants Breakthrough Therapy Designation for Roche’s Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC
US FDA grants Breakthrough Therapy Designation for Roche's Alecensa (alectinib) for first-line treatment of people with ALK-positive NSCLC This second Alecensa Breakthrough Therapy Designation granted is based on phase 3 J-ALEX study Roche announced today that it has received a second Breakthrough Therapy Designation (BTD) from the United States Food and Drug Administration (FDA) for its ALK inhibitor, Alecensa (alectinib).
Physics/Materials Science
03.10.2016
Measuring forces with oscillations
Measuring forces with oscillations
Researchers at ETH Zurich have discovered a peculiar feature in oscillations similar to that of a child's swing. As a result, they have succeeded in outlining a novel principle for small, high-resolution sensors, and have submitted a patent application for it. A child swings on a swing, gaining momentum with its legs.
Medicine/Pharmacology
03.10.2016
Novartis reports over half of psoriasis patients do not reach the achievable treatment goal of clear skin in largest global survey
Global survey of over 8,300 patients shows over half have not achieved clear skin (57%), with the majority taking the historical standard of care treatment *   Majority (84%) face discrimination and
Medicine/Pharmacology - Life Sciences
03.10.2016
First phase III data on Roche’s TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress
First phase III data on Roche's TECENTRIQ (atezolizumab) to feature at the 2016 European Society for Medical Oncology (ESMO) Congress • Superiority results from the phase III OAK study comparing Tecentriq to chemotherapy in a difficult to treat type of lung cancer will be highlighted at the ESMO Presidential Symposium • Investigational cancer immunotherapy-based combination approaches across a range of cancer types to be showcased duri
Medicine/Pharmacology
01.10.2016
Novartis late-breaking data show Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patients
Cosentyx delivers long-lasting clear or almost clear skin (PASI 90 to PASI 100) in the vast majority of patients and continues to show a favorable safety profile over 4 years New data show that with Cosentyx almost 100% of PASI 90 and PASI 100 response rates are maintained from Year 1 to Year 4   Cosentyx significantly superior to Stelara in delivering long-lasting skin clearance in psoriasis over 52 weeks, confirms new JAAD publication The digi
Medicine/Pharmacology - Life Sciences
01.10.2016
Respiratory tract bacterium uncovered as trigger for serious nervous system disease
Respiratory tract bacterium uncovered as trigger for serious nervous system disease
The bacterium Mycoplasma pneumoniae has been under suspicion for quite a while. Now, researchers at the University of Zurich, the University Children's Hospital Zurich, and the Erasmus University in Rotterdam have proved without a doubt that it is the culprit. In fact, mycoplasma is not only responsible for respiratory tract infections such as pneumonia in children and adults, it can also trigger Guillain-Barré syndrome (GBS) in infected individuals.
Astronomy - Media
30.09.2016
Rosetta's momentous end
Rosetta’s momentous end
Rosetta's mission is over: After the last signal at 13:20, the spacecraft was crash-landed on comet Churyumov-Gerasimenko, with the ROSINA instrument from Bern taking measurements right until the very end.
Medicine/Pharmacology - Life Sciences
30.09.2016
Nine professors appointed at ETH Zurich
Nine professors appointed at ETH Zurich
Upon application of the President of ETH Zurich, Professor Lino Guzzella, at its meeting of 28/29 September 2016 the ETH Board appointed nine professors and took note of the resignation of 3 professors and thanked them for their services. Dr Rima Alaifari (*1987), currently a post-doctoral student at ETH Zurich, as Assistant Professor of Applied Mathematics.
Physics/Materials Science - Environment/Sustainable Development
30.09.2016
Rubidium pushes perovskite solar cells to 21.6% efficiency
Rubidium pushes perovskite solar cells to 21.6% efficiency
30.09.16 - EPFL scientists have stabilized perovskite solar cells by integrating rubidium into them.
Business/Economics - Politics
30.09.2016
Seven new professorships at the Department of Economics
The University of Zurich has proven that it can meet several US elite universities at eye level when it comes to recruiting the best talents.
Astronomy
29.09.2016
So long and thanks for the probes
For twelve years, the space probe Rosetta served mankind. The European Space Agency (ESA) mission is now drawing to a close as the probe reaches its final resting place on the target comet Tschuri on September 30, 2016.
Careers/Employment - Physics/Materials Science
28.09.2016
Nine EPFL scientists in Thomson Reuters Highly Cited Researchers
Nine EPFL scientists in Thomson Reuters Highly Cited Researchers
28.09.16 - Nine EPFL scientists have been included in the prestigious Thomson Reuters? list of Highly Cited Researchers.
Medicine/Pharmacology - Business/Economics
28.09.2016
Sandoz invites young entrepreneurs to enter Sandoz HACk, a global competition to help solve healthcare access challenges
Despite significant advances made by modern medicine, universal access to healthcare is still arguably the single largest unmet medical need   Sandoz "HACk" - Healthcare Access Challenge - is a compe
Medicine/Pharmacology - Physics/Materials Science
28.09.2016
Novartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraine
ARISE, first pivotal Phase III study of AMG 334 (erenumab) in episodic migraine prevention, met primary endpoint, showing a statistically significant reduction in monthly migraine days vs placebo   People with episodic migraine experience up to 14 migraine days each month and lose a substantial part of their lives to this debilitating disease   AMG 334 is being co-developed by Novartis and Amgen Basel, September 28, 2016 - Novartis today announc
Social Sciences
28.09.2016
Breaking down the barriers in our minds
Breaking down the barriers in our minds
What role does technology play in equality for people with disabilities? Experts and scientists have been discussing this question in the run-up to the world's first Cybathlon at ETH Zurich.
Astronomy - Event
27.09.2016
Rosetta, ESA’s historic mission, bids farewell after rendez-vous with comet Chury
Bern, 27.09.2016 - Rosetta is set to complete its mission in a controlled descent to the surface of its comet 67P/Churyumov-Gerasimenko on 30 September 2016.
Medicine/Pharmacology - Event
27.09.2016
Nutritionist Professor Johan Auwerx wins the 2016 Marcel Benoist Prize
Bern, 27.09.2016 - Johan Auwerx, Professor at the ETH Lausanne (EPFL), has been awarded this year's Marcel Benoist Prize for his work on mitochondria and their role in the metabolism.
Physics/Materials Science
26.09.2016
SwissFEL in the home stretch: The first electrons are here
SwissFEL in the home stretch: The first electrons are here
SwissFEL building, 24 August 2016: In the control room above the beam tunnel of the free electron X-ray laser SwissFEL, the atmosphere is intense and focussed.